close
close
High growth technology stocks in Asia to see March 2025

High growth technology stocks in Asia to see March 2025

by

Since the global markets deal with inflation concerns and trade policy uncertainties, Asian tech shares attract attention when the economic dynamics changes. In this environment, the determination of opportunities with high growth requires a focus on companies that show resistance and adaptability itself to developing market conditions.

name

Sales growth

Profit growth

Growth assessment

Suzhou TFC optical communication

34.74%

33.49%

★★★★earch

Xi'an Novastar Tech

30.18%

35.32%

★★★★earch

Fososk

36.17%

45.30%

★★★★earch

SEOJIN Systemltd

31.08%

34.32%

★★★★earch

Ewellltd

24.65%

25.30%

★★★★earch

Ascentage Pharma Group International

23.29%

60.86%

★★★★earch

Mental health technologies

21.91%

92.81%

★★★★earch

Jntc

24.99%

104.40%

★★★★earch

Dmall

29.53%

88.37%

★★★★earch

Delton Technology (Guangzhou)

20.25%

29.52%

★★★★earch

Click here to display the full list of 519 shares from our Asian high -growing technician and AI shares.

Here is a look at some of the options of the screener.

Simply wall st -growth level: ★★★★ ☆itch

Overview: Innovent Biologics, Inc. is a biopharmaceutical company that focuses on the development and commercialization of monoclonal antibodies and other drug goods on oncology, ophthalmology, autoimmune, cardiovascular and metabolic diseases in China with a market capitalization of around 67.08 HK billion.

Operations: The company mainly achieves income from its biotechnology segment, which corresponds to CN 7.46 billion of 7.46 billion yen.

Innovent Biologics, a leader in the biotech sector, recently celebrated an important milestone with the consent of Sycume® by the NMPA, an innovative therapy for the thyroid eye disease (TED), which it marked as China's first IGF-1r antibody medication. This approval not only ends a 70-year treatment gap, but also positions innovently at the top in order to tackle autoimmune diseases with high incidence. The commitment of the company for F&E shows itself from its robust pipeline and the latest approvals, including ipilimumab for MSI-H/DMMR-Darm cancer, whereby the strategic focus on oncology and immunotherapy is pointing. Since sales growth in 2024 exceeds 40% compared to the previous year and the result is forecast in order to increase by 44% annually, innovently strategically expands its influence on global markets and improves patient care through groundbreaking treatments.

Sehk: 1801 profit and sales growth as on March 2025

Simply wall st -growth level: ★★★★ ☆itch

Overview: Quectel Wireless Solutions Co., Ltd. is specialized in research and development, the design, production and sales of wireless communication modules and solutions worldwide with a market capitalization of CN 22.50 billion yen.

Related posts:

Pokémon GO: Festival of Colors time plan and bonuses

'End of an era': Microsoft announces the end of Skype, the Internet is reminiscent of golden...

Audio of 911 Call published in Idaho Quadruple Murder Fall